Attila Seyhan named Fox Chase director of translational medicine operations

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Attila Seyhan was named director of translational medicine operations, a newly created position, at Fox Chase Cancer Center.

Seyhan will work closely with Wafik S. El-Deiry, deputy cancer center director for translational research, to manage and promote multiple initiatives, including development of investigator-initiated clinical trials and other translational protocols, protocol writing and manuscript preparation, organization of translational medicine events, support for translational requests for application, and grant preparation and submissions.

He also will work with industry to follow through on investigator-initiated basic and translational letters of intent and concepts. This work will involve collaboration with clinicians, scientists, regulatory personnel, administrators, tech transfer office staff, the grants management office, institutional review board, institutional advancement, and external entities.

A molecular biologist, Seyhan has more than 16 years of experience in drug, target, and biomarker discovery and development, as well as preclinical and clinical translational research, focused on diabetes and metabolic diseases, cancer, inflammation and immunology, molecular virology, and rare genetic diseases.

His most recent position was associate professor at the Translational Research Institute for Metabolism and Diabetes at Florida Hospital in Orlando, FL, and adjunct associate professor at Sanford Burnham Prebys Medical Discovery Institute, in Orlando. In addition, he served as a research affiliate in the department of chemical engineering at Massachusetts Institute of Technology.

YOU MAY BE INTERESTED IN

As NCI and NIH funding is being deliberated in Congress, this year’s 2025 AACR Cancer Progress Report had an unequivocal message: With 20 new anticancer therapeutics, new uses for eight previously approved anticancer therapeutics, two new early detection tools, and several AI-powered diagnostics approved over the span of just one year, cancer research funding yields a good return on investment. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login